New prostate cancer drug tested in small chinese study

NCT ID NCT06136598

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug called MK-5684 (opevesostat) in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. Participants took the drug as tablets, along with other medications to manage side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Opevesostat (MK-5684) tablets, taken with dexamethasone, fludrocortisone, and possibly hydrocortisone
What this could lead to: If successful, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is a very early, small Phase 1 study with only 14 participants, focused on safety and drug levels, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

Peking University First Hospital-Urology ( Site 0001)

Beijing, Beijing Municipality, 100034, China
Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003)

Guangzhou, Guangdong, 510700, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 0002)

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.